Open Access

Promoter methylation analysis of WNT/β-catenin pathway regulators and its association with expression of DNMT1 enzyme in colorectal cancer

  • Nader Mansour Samaei1,
  • Yaghoub Yazdani1,
  • Reza Alizadeh-Navaei2,
  • Hossein Azadeh3 and
  • Touraj Farazmandfar1, 2, 3Email author
Journal of Biomedical Science201421:73

https://doi.org/10.1186/s12929-014-0073-3

Received: 7 June 2014

Accepted: 27 July 2014

Published: 9 August 2014

Abstract

Background

Aberrant DNA methylation as the most important reason making epigenetic silencing of genes is a main mechanism of gene inactivation in patients with colorectal cancer. In this study, we decided to identify promoter methylation status of ten genes encoding WNT negative regulators, and measure the expression of DNMT1 enzyme in colorectal cancer samples.

Results

Aberrant methylation of APC gene was statistically significant associated with age over 50 (p = 0.017), DDK3 with male (p #x003C; 0.0001), SFRP4, WIF1, and WNT5a with increasing tumor stage (p = 0.004, p = 0.029, and p = 0.004), SFRP4 and WIF1 with tumor differentiation (p = 0.009 and p = 0.031) and SFRP2 and SFRP5 with histological type (p = 0.001 and p = 0.025). The increasing number of methylated genes correlated with the expression levels of the DNMT1 mRNA.

Conclusions

The rate of gene promoter methylation of WNT pathway regulators is high in colorectal cancer cells. Hyper-methylation is associated with increased expression of the DNMT1 enzyme.

Keywords

WNT/β-catenin signalingColorectal cancerPromoter methylationDNMT1

Background

Colorectal cancer (CRC) is the second-leading cause of cancer deaths among adults [1]. Aberrant DNA methylation as the most important reason of epigenetic gene silencing is the main mechanism of gene inactivation in patients with CRC [2],[3]. Methylation normally occurs in 5-carbon position of cytosine base within CpG dinucleotide in areas of repetitive DNA outside of exons, introduced by DNA methylases; mainly DNA methyltransferase 1 (DNMT1). Although the DNMT1 enzyme is not the only factor involving in the DNA methylation, but plays a significant role in creating it [4]-[6]. DNA methylation of CpG islands in promoter regions of tumor suppressor genes and DNA repair genes is now recognized as a prevalent feature of human cancers [2].

The developmental WNT/β-catenin signaling pathway is one of the well-known signaling pathways involved in embryogenesis and cancer. A common mechanism of carcinogenesis through WNT/β-catenin signaling is the increased levels of β-catenin protein, which are often results from mutations in the adenomatous polyposis coli (APC) gene (encoding a β-catenin inhibitor) or in the β-catenin gene. Moreover, other mechanisms like functional reduction or loss of negative regulators by DNA methylation or overexpression of oncogenic ligands may contribute to WNT pathway activation in cancer development [7]-[9]. In previous studies, DNA methylation of some WNT inhibitors such as APC, axis inhibition protein 2 (AXIN2), secreted frizzled-related protein (SFRP) family and members of the DICKKOPF (DKK) have been reported in CRC [10]-[13].

As of yet, no comprehensive survey on promoter methylation levels of WNT pathway inhibitors in CRC has been performed, while a potential use of promoter methylation in cancer diagnosis and prediction can be highly regarded. In this study, promoter methylation status of ten genes encoding WNT negative regulators was assayed in CRC samples. These genes including extracellular WNT inhibitors [WNT inhibitory factor-1 (WIF1), DKK3, SFRP2, SFRP4, SFRP5], cytosolic WNT antagonists (AXIN2, APC), nuclear proteins [sex determining region Y related box 7 (SOX7) and 17 (SOX17)], and one WNT ligand [wingless-type MMTV integration site family member 5A (WNT5A)]. To estimate the association between methylation and expression of the DNMT1 enzyme, the expression of this enzyme was measured in the samples.

Methods

Subjects

Samples including 125 Formalin-fixed paraffin-embedded (FFPE) cancerous and adjacent normal tissues (normal tissues distances from the tumor were not measured in this study) obtained from the CRC patients who had surgery between 2005 and 2011 from pathology laboratory. Clinical and pathologic features of patients were extracted from medical records and Tumor staging was determined on the basis of the tumor node metastasis (TNM) classification [14]. Samples with mutational familial adenomatous polyposis or hereditary non-polyposis CRC were excluded of this study. This study was approved of the Clinical Research Ethics Committee in Golestan University of Medical Science.

Methylation analysis

Genomic DNA of microdissected tissue samples was extracted and bisulfite treated using the EpiTect Fast Bisulfite Conversion Kit (Qiagen, Hilden, Germany). Methylation specific PCR (MSP) primers of 10 selected candidate genes were prepared as described previously [15]. MSP was performed using 50 nanograms of modified DNA and Taq DNA polymerase (Roche, Woerden, Netherlands) in 7500 Real-Time PCR system (Applied Biosystem, USA). The methylation was calculated from threshold cycles (CT) values. Ten MSPs for the WNT inhibitors were analytically validated using methylated DNA as positive control (CTs ≤ 25 cycles) and primary keratinocyte DNA as unmethylated controls (CTs > 35>cycles).

DNMTexpression assay

The amplification primers for human DNMT1 and Hypoxanthine-guanine phosphoribosyltransferase (HPRT) cDNA designed by GENE RUNNER software and be reviewed in NCBI and BLAST. DNMT1 Primers sequence including 5′-AGCCAGGTAGCCCTCCTC-3′ as forward and 5′-GACAGCTTAACAGAAAAGGAATG-3′ as reverse with a 141 base pairs (bp) PCR product (GenBank accession number NM_001379.1) and HPRT including 5′-TGGACTAATTATGGACAGGACT-3′ as forward and 5′-CCTGTTGACTGGTCATTACAAT-3′ as reverse with a 219 bp PCR product (GenBank accession number NM_000194). Total RNA was purified from microdissected FFPE tissues using the PureLink FFPE RNA Isolation Kit (Invitrogen, Karlsruhe, Germany). The first strand cDNA was generated using a SuperScript III First-Strand Synthesis SuperMix (Invitrogen, Karlsruhe, Germany). Reverse transcriptase PCR was performed using SYBR Green PCR Master Mix (Fermentas, Lithuania) in triplicate and normalized to HPRT in 7500 detection system. Real-Time PCR conditions consist of 40 cycles (95°C for 15 s, 55°C for 30 s, 72°C for 20 s) after one step initial denaturation (95°C for 10 min). The mean and standard deviation (SD) of DNMT1 mRNA was calculated by 2-ΔCT and the expression fold was calculated by the 2-ΔΔCT and a fold change ≥1.5 was considered as overexpression [16].

Statistical analysis

Statistical analysis was performed by SPSS (version 17.0). Methylation frequencies associations with clinical and pathologic features were analyzed using chi-squared and fisher's exact test. The survival curves were estimated by the Kaplan-Meier method. Association between promoter methylation status with survival was examined by the log-rank test. Survival time was determined from the diagnosis date to the death date due to CRC. A p-value of less than 0.05 was considered statistically significant.

Results

The promoter methylation status

In this study, the promoter methylation was examined on ten genes encoding the WNT pathway inhibitors in CRC tissue samples. Aberrant promoter methylation was detected in 78.4% of patients (98 of 125) (CTs ≤ 25) and none of adjacent non-tumor samples showed methylation (CTs > 35>cycles). The promoter methylation status of the ten genes, including APC, AXIN2, DKK3, SFRP2, SFRP4, SERP5, SOX7, SOX17, WIF1 and WNT5a are respectively 44 samples (35.2%), 41 (32.8%), 50 (40%), 58 (46.4%), 38 (28.8%), 33 (26.4%), 40 (32%), 42 (33.6%), 52 (41.6%) and 28 (22.4%) (Table 1).
Table 1

The association of promoter methylation frequencies and DNMT1 expression with some pathological and clinical features of patients

Clinical and pathological features

N

APC

AXIN2

DKK3

SFRP2

SFRP4

SFRP5

SOX7

SOX17

WIF1

WNT5a

DNMT1expression

N (%)

 

N (%)

 

N (%)

 

N (%)

 

N (%)

 

N (%)

 

N (%)

 

N (%)

 

N (%)

 

N (%)

 

Fold change (%)

 

M

U

p

M

U

P

M

U

p

M

U

p

M

U

p

M

U

p

M

U

p

M

U

p

M

U

p

M

U

p

≥1.5

<1.5

p

All cases

125

44 (35.2)

81 (64.8)

 

41 (32.8)

84 (67.2)

 

50 (40)

75 (60)

 

58 (46.4)

67 (53.6)

 

38 (30.4)

87 (69.6)

 

33 (26.4)

92 (73.6)

 

40 (32)

85 (68)

 

42 (33.6)

83 (66.4)

 

52 (41.6)

73 (58.4)

 

28 (22.4)

97 (77.6)

 

52 (41.6)

73 (58.4)

 

Age

   

.017

                              

<50

18

11 (25)

7 (8.7)

 

7 (17.1)

11 (13.1)

 

8 (16)

10 (13.3)

 

9 (15.5)

9 (13.4)

 

5 (13.2)

13 (14.9)

 

8 (24.2)

10 (10.7)

 

7 (17.5)

11 (12.5)

 

10 (23.8)

8 (9.6)

 

5 (9.6)

13 (17.8)

 

6 (21.4)

12 (12.4)

 

7 (13.5)

11 (15.1)

 

≥50

107

33 (75)

74 (91.3)

 

34 (82.9)

73 (86.9)

 

42 (84)

65 (86.7)

 

49 (84.5)

58 (86.6)

 

33 (86.8)

74 (85.1)

 

25 (75.8)

82 (89.3)

 

33 (82.5)

74 (87.5)

 

32 (76.2)

75 (90.4)

 

47 (90.4)

60 (82.2)

 

22 (78.6)

85 (87.6)

 

45 (86.5)

62 (84.9)

 

Sex

         

<.001

                        

Female

55

21 (47.7)

34 (42)

 

16 (39)

39 (46.4)

 

12 (24)

43 (57.3)

 

28 (48.3)

27 (40.3)

 

13 (34.2)

42 (48.3)

 

17 (51.5)

38 (41.3)

 

19 (47.5)

36 (42.4)

 

15 (35.7)

40 (48.2)

 

23 (44.2)

32 (43.8)

 

12 (42.8)

43 (44.3)

 

21 (40.4)

34 (46.6)

 

Male

70

23 (52.3)

47 (58)

 

25 (61)

45 (53.6)

 

38 (76)

32 (42.7)

 

30 (51.7)

40 (59.7)

 

25 (65.8)

45 (51.7)

 

16 (48.5)

54 (58.7)

 

21 (52.5)

49 (57.6)

 

27 (64.3)

43 (51.8)

 

29 (55.8)

41 (56.2)

 

16 (57.2)

54 (55.7)

 

31 (59.6)

39 (53.4)

 

Tumor location

                                  

Proximal

58

18 (40.9)

40 (49.2)

 

19 (46.3)

39 (46.4)

 

24 (48)

34 (45.3)

 

32 (55.1)

26 (38.8)

 

17 (44.7)

41 (47.1)

 

16 (48.5)

42 (45.7)

 

21 (52.5)

37 (43.5)

 

20 (47.6)

38 (45.8)

 

27 (51.9)

31 (42.5)

 

14 (50)

44 (45.4)

 

28 (53.8)

30 (41.1)

 

Distal

67

26 (59.1)

41 (50.8)

 

22 (53.7)

45 (53.6)

 

26 (52)

41 (54.7)

 

26 (44.9)

41 (61.2)

 

21 (55.3)

46 (52.9)

 

17 (51.5)

50 (54.3)

 

19 (47.5)

48 (56.5)

 

22 (52.4)

45 (54.2)

 

25 (48.1)

42 (57.5)

 

14 (50)

53 (54.6)

 

24 (46.2)

43 (58.9)

 

TNM stage

               

.004

           

.029

  

.004

   

I

17

5 (11.4)

12 (14.8)

 

6 (14.6)

11 (13.1)

 

8 (16)

9 (12)

 

9 (15.5)

8 (11.9)

 

4 (10.5)

13 (14.9)

 

5 (15.2)

12 (13)

 

7 (17.5)

10 (11.8)

 

6 (14.3)

11 (13.3)

 

12 (23.1)

5 (6.8)

 

3 (10.7)

14 (14.4)

 

7 (13.5)

10 (13.7)

 

II

39

17 (38.6)

22 (27.2)

 

11 (26.8)

28 (33.3)

 

15 (30)

24 (32)

 

18 (31)

21 (31.3)

 

10 (26.3)

29 (33.3)

 

12 (36.4)

27 (29.3)

 

13 (32.5)

26 (30.6)

 

10 (23.8)

29 (34.9)

 

14 (26.9)

25 (34.3)

 

5 (17.8)

34 (35.1)

 

13 (25)

26 (35.6)

 

III

61

18 (40.9)

43 (53.1)

 

19 (46.4)

42 (50)

 

22 (44)

39 (52)

 

25 (43.1)

36 (53.8)

 

17 (44.7)

44 (50.6)

 

13 (39.4)

48 (52.2)

 

16 (40)

45 (52.9)

 

24 (57.1)

37 (44.6)

 

25 (48.1)

36 (49.3)

 

14 (50)

47 (48.4)

 

27 (51.9)

34 (46.6)

 

IV

8

4 (9.1)

4 (4.9)

 

5 (12.2)

3 (3.6)

 

5 (10)

3 (4)

 

6 (10.4)

2 (3)

 

7 (18.5)

1 (1.2)

 

3 (9)

5 (5.5)

 

4 (10)

4 (4.7)

 

2 (4.8)

6 (7.2)

 

1 (1.9)

7 (9.6)

 

6 (21.5)

2 (2.1)

 

5 (9.6)

3 (4.1)

 

Tumor differentiation

               

.009

           

.031

      

Low

11

4 (9.1)

7 (8.7)

 

5 (12.2)

6 (7.1)

 

3 (6)

8 (10.7)

 

4 (6.9)

7 (10.4)

 

6 (15.8)

5 (5.7)

 

3 (9.1)

8 (8.7)

 

2 (5)

9 (10.6)

 

7 (16.7)

4 (4.8)

 

1 (1.9)

10 (13.7)

 

3 (10.7)

8 (8.2)

 

4 (7.7)

7 (9.6)

 

Moderate

89

30 (68.2)

59 (72.8)

 

27 (65.9)

62 (73.8)

 

39 (78)

50 (66.7)

 

43 (74.1)

46 (68.7)

 

20 (52.6)

69 (79.3)

 

22 (66.7)

67 (72.8)

 

32 (80)

57 (67.1)

 

30 (71.4)

59 (71.1)

 

37 (71.2)

52 (71.2)

 

18 (64.3)

71 (73.2)

 

36 (69.2)

53 (72.6)

 

High

25

10 (22.7)

15 (18.5)

 

9 (21.9)

16 (19.1)

 

8 (16)

17 (22.6)

 

11 (19)

14 (20.9)

 

12 (31.6)

13 (15)

 

8 (24.2)

17 (18.5)

 

6 (15)

19 (22.3)

 

5 (11.9)

20 (24.1)

 

14 (26.9)

11 (15.1)

 

7 (25)

18 (18.6)

 

12 (23.1)

13 (17.8)

 

Histological type

            

.001

     

.025

               

Non-mucinous

98

30 (68.2)

68 (84)

 

34 (82.9)

64 (76.2)

 

39 (78)

59 (78.7)

 

53 (91.4)

45 (67.2)

 

30 (78.9)

68 (78.2)

 

21 (63.6)

77 (83.7)

 

34 (85)

64 (75.3)

 

32 (76.1)

66 (79.5)

 

37 (71.2)

61 (83.6)

 

19 (67.8)

79 (81.4)

 

35 (67.3)

63 (86.3)

 

Mucinous

27

14 (31.8)

13 (16)

 

7 (17.1)

20 (23.8)

 

11 (22)

16 (21.3)

 

5 (8.6)

22 (32.8)

 

8 (21.1)

19 (21.8)

 

12 (36.4)

15 (16.3)

 

6 (15)

21 (24.7)

 

10 (23.9)

17 (20.5)

 

15 (28.8)

12 (16.4)

 

9 (32.2)

18 (18.6)

 

17 (32.7)

10 (13.7)

 

N; Number of cases, M; Methylated, U; Unmethylated, p; p value.

Only significant P values are described.

The correlation with clinical and pathological features

We analyzed methylation status relationship of these genes with some patients’ clinical and pathological features. As the results in Table 1 show, APC gene methylation is statistically associated with age over 50 (p = 0.017). DDK3 gene methylation is also significantly associated with male (p #x003C; 0.0001). Methylation of SFRP4, WIF1 and WNT5a genes were meaningfully associated with increasing tumor stage (p = 0.004, p = 0.029 and p = 0.004). Moreover, methylation frequency of SFRP4 and WIF1 genes were also significantly associated with tumor differentiation (p = 0.009 and p = 0.031). The SFRP2 and SFRP5 genes methylation was correlated with histological type, therefore the frequency of methylation is higher in non-mucinous type (p = 0.001 and p = 0.025). There is no significant association between genes methylation status and tumor location. There is also no significant association between DNMT1 expression and clinicopathological features.

Follow-up information was available on 112 CRC patients for 42 ± 25 (3 to 80) months. Univariate analysis by the Kaplan-Meier curves indicated, among the ten genes, only WIF1 has a negative correlation between promoter methylation and survival in CRC patients (P #x003C; 0.001) (Figure 1).
Figure 1

Kaplan-Meier curves for overall survival in colorectal carcinomas. Kaplan-Meier curves for cumulative survival rate of patients according to the promoter methylation in all the colorectal carcinomas. Among the ten genes, only patients with methylated WIF1 gene promoter had shorter overall survival. M, Methylated; U,Unmethylated.

Correlation of DNMToverexpression with the increasing number of methylated genes

We assayed the expression levels of DNMT1 enzyme mRNA in 125 tumor and adjacent normal tissues. As Figure 2 shows, DNMT1 expression in CRC tissues (2.01 ± 0.82) is statistically higher than the non-tumor mucosa (1.02 ± 0.52) (P #x003C; 0.001), as well as methylated (2.91 ± 0.95) than non-methylated samples (1.07 ± 0.44) (P #x003C; 0.001). We also investigated the expression levels of DNMT1 mRNA within methylated samples and was compared to fold changes of DNMT1 expression. For this purpose, methylated samples were divided into six groups according to the number of methylated genes. The results show; the expression level of the DNMT1 mRNA was directly correlated with the increasing number of methylated genes in methylated samples (Table 2).
Figure 2

The expression levels of DNMT1 enzyme mRNA in colorectal carcinomas. The level of DNMT1 expression in methylated samples is higher than non-methylated as well as tumor samples than non-tumor.

Table 2

The relationship of DNMT1 expression with the number of methylated genes

Number of methylated genes

DNMT1-overexpressed cases

Odds ratio (CI 95%)

N (%)

Fold change (mean ± SD)

1 (n = 35)

13 (37.1)

1.52 ± 1.12

1

2 (n = 19)

11 (57.9)

2.12 ± 1.56

2.3 (0.7-7.2)

3 (n = 16)

9 (56.2)

2.02 ± 1.78

2.1 (0.6-7.2)

4 (n = 10)

6 (60)

3.61 ± 1.89

2.5 (0.6-10.7)

5 (n = 11)

7 (63.6)

3.06 ± 1.55

2.9 (0.7-12.9)

6 (n = 7)

6 (85.7)

4.14 ± 1.28

10.1 (1.1-93.9)*

*p value <0.05, CI, confidence interval.

Discussion

Today, the epigenetic markers of causing changes in the WNT signaling pathways are highly considered, both in the detection and prognosis of the disease process in many cancers [17]. The study of methylation as a reversible major change during the early stages of tumor angiogenesis is under investigation [18],[19]. Hence, we were going to investigate the variability of promoter methylation of WNT negative regulators to estimate these changes in CRC. In this study, the frequency of promoter methylation of APC gene (35.2%) is higher than the frequency obtained during the studies of Chen et al. (17.9%), Esteller et al. (18%) and Arnold et al. (28%) [10],[20],[21]. On the other hand, this frequency is less than the frequencies in Studies of Iacopetta et al. (41.1%) and Fu et al. (41.7%) [22],[23]. Because, changes in the APC gene are the most common cause of CRC, 35.2% methylation can also be significant. The AXIN2 methylation frequency of this study (32.8%) compared to prevalence of the Koinuma et al. study (25%) had higher level [11]. It seems that frequency of DKK3 promoter methylation (40%) is less than Yu et al. study (52%). Unlike Yu et al. study, we reported that the increasing of promoter methylation frequency was significant in men, but we did not find a significant association between promoter methylation frequencies with cancer progression stages [12]. The promoter methylation frequency of SFRP2, 4, 5 genes in this study (46.4%, 28.8%, and 26.4%) compared to the results of Qi et al. study (82.8%, 32.4% and 54.3%) is much lower [13]. Low frequency of WIF1 promoter methylation in this study (41.6%) compared to the Lee et al. study (74%) was also considerable [24]. There are few differences between frequency of WNT5a promoter methylation in this study (22.4%) and Rawson et al. study (18.8%). In both studies, the frequency of promoter methylation is significantly associated with female gender [25] (Table 3). Univariate analysis indicates that WIF1 promoter methylation is prognostic factors for overall survival in colorectal carcinomas. The results of this study show that DNMT1 expression levels in methylated samples are higher from unmethylated, unlike Ting et al. study in which they believed the DNMT1 enzyme has no effect on the maintenance of DNA methylation [26]. The increasing expression of the DNMT1 enzyme weakly correlates with the increasing number of methylated genes (Table 2). On the other hand, there have not been many studies on correlation between DNMT1 expression and methylation, which makes it difficult to evaluate our work; Therefore, It needs more study.
Table 3

The comparison of promoter methylation of this study and other reports in colorectal carcinomas

Genes

Number of methylated samples (%)

References (frequency of gene)

APC

44 (35.2)

Esteller et al. [21] (18%); Arnold et al. [10] (28%); Chen et al. [20] (17.9%); Iacopetta et al. [22] (41.1%) and Fu et al. [23] (41.7%)

AXIN2

41 (32.8)

Koinuma et al. [11] (25%)

DKK3

50 (40)

Yu et al. [12] (52%)

SFRP2

58 (46.4)

Qi et al. [13] (82.8%)

SFRP4

38 (30.4)

Qi et al. [13] (32.4%)

SFRP5

33 (26.4)

Qi et al. [13] (54.3%)

SOX7

40 (32)

No Reference

SOX17

42 (33.6)

No Reference

WIF1

52 (41.6)

Lee et al. [24] (74%)

WNT5a

28 (22.4)

Rawson et al. [25] (18.8%)

Conclusions

We have shown that the rate of gene methylation in cancer cells increases can contribute to cancer development and progression. Methylation may also increase due to increased expression or mutations in the methyltransferase enzyme or their regulatory proteins in cancer cells. Knowing the rate of DNMT1 enzyme overexpression in human cancers, particularly in cases of hyper-methylated might be useful as part of the diagnostic and prognostic evaluation in human cancers.

Authors’ contributions

NMS carried out the Real-Time PCR, data analysis and manuscript preparation. YY, RAN and HA participated project design, data analysis and manuscript preparation. TF supervised experimental design, data analysis and reviewed manuscript. All authors read and approved the final manuscript.

Declarations

Acknowledgments

This study supported by a grant from the Research and Technology Department in Golestan University of Medical Sciences.

Authors’ Affiliations

(1)
Golestan Research Center of Gastroenterology and Hepatology-GRCGH, Golestan University of Medical Sciences
(2)
Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences
(3)
Cancer Research Center, Mazandaran University of Medical Sciences

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.View ArticlePubMedGoogle Scholar
  2. Issa J-P: CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004, 4: 988-993. 10.1038/nrc1507.View ArticlePubMedGoogle Scholar
  3. Kondo Y, Issa J-PJ: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004, 23: 29-39. 10.1023/A:1025806911782.View ArticlePubMedGoogle Scholar
  4. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009, 361: 2449-2460. 10.1056/NEJMra0804588.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Ting AH, Jair K, Schuebel KE, Baylin SB: Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. Cancer Res. 2006, 66: 729-735. 10.1158/0008-5472.CAN-05-1537.View ArticlePubMedGoogle Scholar
  6. Jair K-W, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen R-WC, Baylin SB, Schuebel KE: De novo CpG island methylation in human cancer cells. Cancer Res. 2006, 66: 682-692. 10.1158/0008-5472.CAN-05-1980.View ArticlePubMedGoogle Scholar
  7. Smith JJ, Deane NG, Dhawan P, Beauchamp RD: Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Surgery. 2008, 144: 353-366. 10.1016/j.surg.2008.05.007.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Veeck J, Dahl E: Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta. 1825, 2012: 18-28.Google Scholar
  9. Bienz M, Clevers H: Linking colorectal cancer to Wnt signaling. Cell. 2000, 103: 311-320. 10.1016/S0092-8674(00)00122-7.View ArticlePubMedGoogle Scholar
  10. Arnold CN, Goel A, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR: APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther. 2004, 3: 960-964. 10.4161/cbt.3.10.1113.View ArticlePubMedGoogle Scholar
  11. Koinuma K, Yamashita Y, Liu W, Hatanaka H, Kurashina K, Wada T, Takada S, Kaneda R, Choi YL, Fujiwara S-I, Miyakura Y, Nagai H, Mano H: Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability. Oncogene. 2006, 25: 139-146.PubMedGoogle Scholar
  12. Yu J, Tao Q, Cheng YY, Lee KY, Ng SSM, Cheung KF, Tian L, Rha SY, Neumann U, Röcken C, Ebert MPA, Chan FKL, Sung JJY: Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer. 2009, 115: 49-60. 10.1002/cncr.23989.View ArticlePubMedGoogle Scholar
  13. Qi J, Zhu Y-Q, Luo J, Tao W-H: Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol. 2006, 12: 7113-7117.PubMed CentralPubMedGoogle Scholar
  14. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997, 80: 1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
  15. Van der Meide WF, Snellenberg S, Meijer CJLM, Baalbergen A, Helmerhorst TJM, van der Sluis WB, Snijders PJF, Steenbergen RDM: Promoter methylation analysis of WNT/β-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. Gynecol Oncol. 2011, 123: 116-122. 10.1016/j.ygyno.2011.06.015.View ArticlePubMedGoogle Scholar
  16. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.View ArticlePubMedGoogle Scholar
  17. Ying Y, Tao Q: Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics. 2009, 4: 307-312. 10.4161/epi.4.5.9371.View ArticlePubMedGoogle Scholar
  18. Paluszczak J, Baer-Dubowska W: Epigenetic diagnostics of cancer–the application of DNA methylation markers. J Appl Genet. 2006, 47: 365-375. 10.1007/BF03194647.View ArticlePubMedGoogle Scholar
  19. Kulis M, Esteller M: DNA methylation and cancer. Adv Genet. 2010, 70: 27-56. 10.1016/B978-0-12-380866-0.60002-2.View ArticlePubMedGoogle Scholar
  20. Chen J, Röcken C, Lofton-Day C, Schulz H-U, Müller O, Kutzner N, Malfertheiner P, Ebert MPA: Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis. 2005, 26: 37-43. 10.1093/carcin/bgh280.View ArticlePubMedGoogle Scholar
  21. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Gonzalez S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB, Herman JG: Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000, 60: 4366-4371.PubMedGoogle Scholar
  22. Iacopetta B, Grieu F, Li W, Ruszkiewicz A, Caruso M, Moore J, Watanabe G, Kawakami K: APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. Int J Cancer. 2006, 119: 2272-2278. 10.1002/ijc.22237.View ArticlePubMedGoogle Scholar
  23. Fu X, Li J, Li K, Tian X, Zhang Y: Hypermethylation of APC promoter 1A is associated with moderate activation of Wnt signalling pathway in a subset of colorectal serrated adenomas. Histopathology. 2009, 55: 554-563. 10.1111/j.1365-2559.2009.03411.x.View ArticlePubMedGoogle Scholar
  24. Lee BB, Lee EJ, Jung EH, Chun H-K, Chang DK, Song SY, Park J, Kim D-H: Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res. 2009, 15: 6185-6191. 10.1158/1078-0432.CCR-09-0111.View ArticlePubMedGoogle Scholar
  25. Rawson JB, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, Parfrey PS, Young JP, Pollett A, Green RC, Gallinger S, McLaughlin JR, Knight JA, Bapat B: Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients. Br J Cancer. 2011, 104: 1906-1912. 10.1038/bjc.2011.165.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Ting AH, Jair K, Suzuki H, Yen R-WC, Baylin SB, Schuebel KE: CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet. 2004, 36: 582-584. 10.1038/ng1365.View ArticlePubMedGoogle Scholar

Copyright

© Mansour Samaei et al.; licensee BioMed Central. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement